In addition, whole-exome sequencing studies have unveiled somatic mutations in the SETD2 gene across various malignant tumors; this suggests that SETD2 inactivation is linked to tumorigenesis in these organs, even if less frequently [16]. This evidence concerns the gene SETD2 and cancer.